Clinical trials: Arrhythmogenic Right Ventricular Dysplasia, active
Cardiomyopathies, Heart Diseases
PKP2-ACM Natural History Study
The goal of this study is to describe the natural history and clinical events for patients who have Arrhythmogenic Cardiomyopathy with Pathogenic Plakophilin-2 Variants (PKP2-ACM) managed with standard of care.
- Conditions
- Cardiomyopathies, Heart Diseases, Cardiovascular Diseases, Genetic Diseases
- Trial name
- NCT06644742
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 36 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy, Cardiac Sarcoidosis, Hypertensive Heart Disease
- Trial name
- CHIEFTain (NCT06409585)
- Testing
- 68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR, Echocardiogram, Cardiac MRI
- Where
- United Kingdom
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Non-ischemic Cardiomyopathy, Cardiomyopathies
Cardiovascular Multimodality Imaging Study
Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis.
- Conditions
- Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy
- Trial name
- NCT06610019
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Montefiore Medical Center
Arrhythmogenic Cardiomyopathy (AC, ARVD/C)
Cardiac Rehabilitation in Patients With High-Genetic-Risk Arrhythmogenic Cardiomyopathy: The HGEN-CARE-AC Trial
The goal of this clinical trial is to evaluate a structured and personalized cardiac rehabilitation program for patients diagnosed with arrhythmogenic cardiomyopathy (ACM) who carry high-risk genetic mutations.
- Trial name
- HGEN-CARE-AC (NCT07708311)
- Testing
- Cardiac Rehabilitation Programme
- Volunteers
- 70 people
- Sponsor
- Juan Jiménez Jáimez
Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Ventricular Tachycardia (VT)
Treatment Registry of Arrhythmias, Complications and Electrocardiograms in Arrhythmogenic CardioMyopathies
TRACE-ACM is a multicenter, retrospective, observational study of patients with arrhythmogenic cardiomyopathy who received an implantable cardioverter-defibrillator (ICD) and had documented ventricular tachyarrhythmias.
- Conditions
- Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Ventricular Tachycardia (VT), Ventricular Fibrillation, ICD
- Trial name
- TRACE-ACM (NCT07688200)
- Volunteers
- 300 people
- Sponsor
- Policlinico Casilino ASL RMB
Cardiomyopathies, Dilated Cardiomyopathy
Pediatric Cardiomyopathy Mutation Analysis
The goal of this protocol is to obtain information from individuals with cardiomyopathy and from their families in order to elucidate the molecular genetics of this disorder.
- Conditions
- Cardiomyopathies, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy
- Trial name
- NCT02432092
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Indiana University
Arrhythmogenic Right Ventricular Dysplasia
Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy
The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation.
- Trial name
- LI-ARVC (NCT05209776)
- Testing
- Peripheral immunological assessment on venous blood, Immunological assessment carried out on intracardiac material
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Toulouse
Arrhythmogenic Right Ventricular Dysplasia, Brugada Syndrome
Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders
Every week in the UK, 12 apparently healthy and fit individuals under the age of 35 die suddenly, a tragic event known as sudden cardiac death (SCD).
- Conditions
- Arrhythmogenic Right Ventricular Dysplasia, Brugada Syndrome, Cardiac Channelopathy
- Trial name
- NCT04257994
- Testing
- obtaining a buccal smear sample
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- St. George's Hospital, London
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Dilated
National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry
The goal of this observational study is to develop a registry of Brazilian patients with hereditary cardiovascular diseases, combining clinical and genomic data.
- Conditions
- Cardiomyopathy, Hypertrophic, Cardiomyopathy, Dilated, Cardiomyopathy Restrictive, Arrhythmogenic Right Ventricular Dysplasia
- Trial name
- RENOMICA-Hcor (NCT06546137)
- Testing
- whole genome sequencing
- Where
- 27 sites in Brazil
- Volunteers
- 1,211 people
- Sponsor
- Hospital do Coracao
Arrhythmogenic Right Ventricular Cardiomyopathy, FAPI PET
FAPI PET/CT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease associated with fibrofatty myocardial replacement, ventricular arrhythmias, and an increased risk of sudden cardiac death.
- Conditions
- Arrhythmogenic Right Ventricular Cardiomyopathy, FAPI PET, Cardiac Magnetic Resonance Imaging
- Trial name
- FAPI-ARVC (NCT07563660)
- Testing
- 68Ga-DOTA-SA-FAPI PET/CT
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Istanbul University - Cerrahpasa
Arrhythmogenic Right Ventricular Cardiomyopathy, Cardiomyopathies
Mayo AVC Registry and Biobank
Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous.
- Conditions
- Arrhythmogenic Right Ventricular Cardiomyopathy, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases
- Trial name
- NCT03049254
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.
- Trial name
- NCT05885412
- Testing
- RP-A601
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Arrhythmogenic Right Ventricular Cardiomyopathy
Arrhythmogenic Activity During Exercise in ARVC Patients
Current guidelines advocate that ARVC patients, typically young and active individuals with a significant history of competitive endurance sports, cease endurance training in favour of activities with low cardiac burden such as…
- Trial name
- NCT06040242
- Testing
- Exercise
- Where
- Switzerland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Swiss Federal Institute of Technology
Heart Disease Structural Disorder, Ventricular Tachycardia
Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia
Sudden cardiac death (SCD) due to recurrent ventricular tachycardia (VT) is an important clinical sequela in patients with structural heart disease.
- Conditions
- Heart Disease Structural Disorder, Ventricular Tachycardia, Cardiomyopathy, Dilated, Sarcoidosis
- Trial name
- CAAD-VT (NCT05524077)
- Testing
- Ablation, Anti-arrhythmic Drugs (AADs)
- Where
- 9 sites in Australia
- Volunteers
- 162 people
- Sponsor
- Western Sydney Local Health District
Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype…
- Trial name
- TaRGET (NCT06174220)
- Testing
- Tideglusib
- Where
- 17 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Hamilton Health Sciences Corporation
Arrhythmogenic Right Ventricular Dysplasia
Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
Arrhythmogenic right ventricular dysplasia (ARVD) is a rare cardiomyopathy characterized by the progressive replacement of cardiomyocytes by fatty and fibrous tissue in the right ventricle (RV).
- Trial name
- BRAVE (NCT03593317)
- Testing
- Spironolactone
- Where
- 13 sites in France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Inherited Cardiac Arrythmias, Long QT Syndrome (LQTS)
Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
Human induced pluripotent stem cells (hiPSCs) have driven a paradigm shift in the modeling of human disease; the ability to reprogram patient-specific cells holds the promise of an enhanced understanding of disease mechanisms and…
- Conditions
- Inherited Cardiac Arrythmias, Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
- Trial name
- NCT02413450
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Arrhythmogenic Cardiomyopathy, PKP2-ACM
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
- Conditions
- Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
- Trial name
- NCT06109181
- Testing
- LX2020
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Lexeo Therapeutics
Arrhythmogenic Cardiomyopathy, PKP2-ACM
Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant
The primary objective of this Phase 1/2 long-term follow-up (LTFU) study is to assess the long-term safety and tolerability of LX2020 for the treatment of arrhythmogenic cardiomyopathy (ACM) due to a plakophilin-2 gene (PKP2)…
- Conditions
- Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
- Trial name
- GRIT-PKP2 (NCT07050160)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lexeo Therapeutics
Arrhythmogenic Cardiomyopathy, PKP2-ACM
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.
- Conditions
- Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
- Trial name
- SNAPSHOT- PKP2 (NCT06976606)
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Lexeo Therapeutics